TWI910174B - Ｇｌｐ-１和ｇｉｐ受體雙重激動劑化合物及其應用 - Google Patents

Ｇｌｐ-１和ｇｉｐ受體雙重激動劑化合物及其應用

Info

Publication number
TWI910174B
TWI910174B TW110119502A TW110119502A TWI910174B TW I910174 B TWI910174 B TW I910174B TW 110119502 A TW110119502 A TW 110119502A TW 110119502 A TW110119502 A TW 110119502A TW I910174 B TWI910174 B TW I910174B
Authority
TW
Taiwan
Prior art keywords
amino acid
acid residue
glp
oeg
analogue
Prior art date
Application number
TW110119502A
Other languages
English (en)
Chinese (zh)
Other versions
TW202144393A (zh
Inventor
吳方舟
王雷
黃旭超
吳然
劉仁志
花海清
Original Assignee
大陸商北京拓界生物醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商北京拓界生物醫藥科技有限公司 filed Critical 大陸商北京拓界生物醫藥科技有限公司
Publication of TW202144393A publication Critical patent/TW202144393A/zh
Application granted granted Critical
Publication of TWI910174B publication Critical patent/TWI910174B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110119502A 2020-05-29 2021-05-28 Ｇｌｐ-１和ｇｉｐ受體雙重激動劑化合物及其應用 TWI910174B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010472577.8 2020-05-29
CN202010472577 2020-05-29
CN202110335100 2021-03-29
CN202110335100.X 2021-03-29

Publications (2)

Publication Number Publication Date
TW202144393A TW202144393A (zh) 2021-12-01
TWI910174B true TWI910174B (zh) 2026-01-01

Family

ID=78745631

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110119502A TWI910174B (zh) 2020-05-29 2021-05-28 Ｇｌｐ-１和ｇｉｐ受體雙重激動劑化合物及其應用

Country Status (11)

Country Link
US (1) US20230190879A1 (https=)
EP (1) EP4159750A4 (https=)
JP (1) JP2023526973A (https=)
KR (1) KR20230018395A (https=)
CN (3) CN114222755B (https=)
AU (1) AU2021278157A1 (https=)
BR (1) BR112022023834A2 (https=)
CA (1) CA3180215A1 (https=)
MX (1) MX2022014368A (https=)
TW (1) TWI910174B (https=)
WO (1) WO2021239082A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
US20250115654A1 (en) * 2021-11-12 2025-04-10 Fujian Shengdi Pharmaceutical Co., Ltd. Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
WO2023207106A1 (zh) * 2022-04-29 2023-11-02 苏州星洲生物科技有限公司 Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
CN115806593B (zh) * 2022-09-23 2023-09-05 成都普康生物科技有限公司 一种脂肪酸链修饰的双受体激动剂及其用途
CN116120425A (zh) * 2022-12-27 2023-05-16 南京赛诺生物技术有限公司 一种glp-1/gip受体双重激动剂及其应用
CN118056839B (zh) * 2023-01-17 2024-11-29 广东众生睿创生物科技有限公司 带有修饰结构的多肽及其应用
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
CN116496361B (zh) * 2023-06-25 2023-09-15 北京科翔中升医药科技有限公司 氘代模拟肽gip和glp-1双受体激动剂药物及用途
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
WO2025242218A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 一种多肽激动剂，其制备方法及医药用途
CN120081924A (zh) * 2024-07-11 2025-06-03 中国药科大学 Glp-1r受体激动多肽化合物及其用途
CN119390784A (zh) * 2024-07-11 2025-02-07 中国药科大学 一种双激动多肽化合物及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103764673A (zh) * 2011-06-10 2014-04-30 北京韩美药品有限公司 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
CN104583232B (zh) * 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
CN107108715A (zh) * 2014-10-24 2017-08-29 默沙东公司 胰高血糖素和glp‑1受体的共激动剂
WO2016131893A1 (en) * 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
US10946074B2 (en) * 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN112351994B (zh) * 2019-04-11 2024-06-07 江苏豪森药业集团有限公司 一种多受体激动剂及其医药用途
CN111825758B (zh) * 2019-04-19 2024-11-22 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103764673A (zh) * 2011-06-10 2014-04-30 北京韩美药品有限公司 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., ... & Kruse, T. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry 58(18) 2015 7370-7380. *

Also Published As

Publication number Publication date
CN118530333A (zh) 2024-08-23
MX2022014368A (es) 2022-12-15
EP4159750A1 (en) 2023-04-05
JP2023526973A (ja) 2023-06-26
TW202144393A (zh) 2021-12-01
AU2021278157A1 (en) 2022-11-24
WO2021239082A1 (zh) 2021-12-02
CN114222755B (zh) 2024-06-11
US20230190879A1 (en) 2023-06-22
CN118754965A (zh) 2024-10-11
CN114222755A (zh) 2022-03-22
BR112022023834A2 (pt) 2022-12-27
CA3180215A1 (en) 2021-12-02
EP4159750A4 (en) 2023-10-18
KR20230018395A (ko) 2023-02-07

Similar Documents

Publication Publication Date Title
TWI910174B (zh) Ｇｌｐ-１和ｇｉｐ受體雙重激動劑化合物及其應用
AU2020256648B2 (en) Multi-receptor agonist and medical use thereof
CN113383014B (zh) 双受体重激动剂化合物及其药物组合物
CN111825758B (zh) Glp-1和gip共激动剂化合物
EP4431522A1 (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
TW202502808A (zh) Glp-1、gip和gcg受體三激動劑及其應用
RU2848325C1 (ru) Соединение с двойной агонистической активностью в отношении рецепторов glp-1 и gip и его применение
HK40069563B (zh) Glp-1和gip受体双重激动剂化合物及其应用
RU2816492C2 (ru) Мультирецепторный агонист и его медицинское применение
HK40069563A (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
EA053272B1 (ru) Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение
HK40051504B (zh) 双受体重激动剂化合物及其药物组合物
HK40043112B (zh) 一种多受体激动剂及其医药用途
HK40051504A (en) Dual receptor-acting agonist compounds and pharmaceutical composition thereof
TW202613157A (zh) 一種多肽激動劑，其製備方法及醫藥用途
HK40043112A (en) Multi-receptor agonist and medical use thereof